Cargando…
Pancreatic cancer resistance conferred by stellate cells: looking for new preclinical models
Pancreatic ductal adenocarcinoma (PDAC) has an extremely poor response to chemo- and (modest-dose conventionally fractionated) radio-therapy. Emerging evidence suggests that pancreatic stellate cells (PSCs) secrete deoxycytidine, which confers resistance to gemcitabine. In particular, deoxycytidine...
Autores principales: | Che, Pei Pei, Gregori, Alessandro, Firuzi, Omidreza, Dahele, Max, Sminia, Peter, Peters, Godefridus J., Giovannetti, Elisa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7398063/ https://www.ncbi.nlm.nih.gov/pubmed/32775041 http://dx.doi.org/10.1186/s40164-020-00176-0 |
Ejemplares similares
-
Comment on: Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis
por: Che, Pei Pei, et al.
Publicado: (2020) -
Role of c-MET Inhibitors in Overcoming Drug Resistance in Spheroid Models of Primary Human Pancreatic Cancer and Stellate Cells
por: Firuzi, Omidreza, et al.
Publicado: (2019) -
Radiobiological Aspects of FLASH Radiotherapy
por: Hageman, Eline, et al.
Publicado: (2022) -
Biodegradable Ultrasmall-in-Nano Architectures Loaded with Cisplatin Prodrug in Combination with Ionizing Radiation Induces DNA Damage and Apoptosis in Pancreatic Ductal Adenocarcinoma
por: Che, Pei Pei, et al.
Publicado: (2022) -
hENT-1 Expression and Localization Predict Outcome After Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients
por: Meijer, Laura L., et al.
Publicado: (2016)